GlycoMimetics (GLYC) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments
November 7, 2019 8:24 AM ESTAdvanced its Phase 3 program for uproleselan in acute myeloid leukemia (AML) through both Company-sponsored and NCI-sponsored clinical trials Announced abstracts accepted for presentation in December at the Annual Meeting of the American Society of Hematology (ASH) in Orlando, which continue to demonstrate key role of E-selectin ligand and potential value of uproleselan in AML Announced that Pfizers Phase 3 clinical trial evaluating rivipansel in sickle cell disease (SCD) failed to meet the primary endpoint and key secondary endpoints Eliminated certain non-core research and development spending commitments
... More
